secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0000950170-23-034741
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M
-----------------------------------------------------------------------

- VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.
- VK2809 showed significant reductions in LDL-C and triglycerides; Phase 2b 52-week biopsy results expected 1H24.
- Phase 2 study of obesity candidate VK2735 to start 3Q23; Phase 1 oral formulation data expected 4Q23.
- Net loss $19.2M ($0.19 loss/share) vs $17.4M ($0.23) in Q2 2022; R&D spend $13.9M, G&A $9.8M.
- Ended Q2 with $393M cash, boosted by $288M stock offering; cash runway through multiple catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/0000950170-23-034741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023034741/vktx-20230726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer